# chat_messages

session_id: 6f325b93-ac50-4041-ae1a-d3453ec890ec
timestamp: 2024-11-24 14:35:17.798477
message:
  The context does not provide specific causes of amenia, as it seems there might be a confusion between amenia and amenorrhea. If you're referring to amenorrhea, the text mentions that the most productive cause is the cessation of the force by which ovarian vesicles are evolved and matured. This means that if the vital action that matures the ova is destroyed, menstruation cannot occur. Additionally, the text suggests that amenorrhea can often be associated with anemia, a condition characterized by a lack of healthy red blood cells in the body. However, it's important to note that amenorrhea can be caused by a variety of factors, not just anemia or issues with ovarian vesicle maturation. These can include stress, changes in weight, certain medications, and hormonal imbalances, among others. If you're referring to "amenia," the context does not provide enough information to answer the question.

  📚 Sources Used:

  • Obstetrics—the Science and the Art
    Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10402504

  • Medicine in Paris—Trousseau on Iron
    Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10351768

  • Esquirol on Insanity
    Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10355787

sources_used:
  [{"title": "Obstetrics\u2014the Science and the Art", "source": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10402504", "timestamp": "2024-11-24T14:35:17.797972"}, {"title": "Obstetrics\u2014the Science and the Art", "source": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10402504", "timestamp": "2024-11-24T14:35:17.797988"}, {"title": "Medicine in Paris\u2014Trousseau on Iron", "source": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10351768", "timestamp": "2024-11-24T14:35:17.797991"}, {"title": "Esquirol on Insanity", "source": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10355787", "timestamp": "2024-11-24T14:35:17.797994"}]


session_id: a6b236c3-ed6f-49f7-a587-c404ee77fb3c
timestamp: 2024-11-24 14:35:58.048343
message:
  Lung cancer is a type of malignant tumor that has become a leading cause of harm to human life and health, surpassing cardiovascular diseases. It is the most common cause of cancer-related deaths globally and in the United States. The incidence and mortality of lung cancer rank first among malignant tumors.

  Lung cancer is primarily divided into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for about 80% of all lung cancer cases. A subtype of NSCLC, lung adenocarcinoma (LUAD), accounts for more than 40% of lung cancer cases.

  The main clinical treatments for NSCLC include surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, and traditional Chinese medicine. Surgery and chemotherapy are usually suitable for the early stages of NSCLC. However, most patients are diagnosed in the middle and advanced stages, and almost half of the patients have distant metastases. For these advanced stages, treatment usually involves chemotherapy or targeted therapy.

  Despite significant progress in the diagnosis and therapy of lung cancer over the last decade, the mortality rate remains high. This is partly because the early symptoms of lung cancer are often insidious, leading to a low detection rate. Most patients are diagnosed at an advanced stage, which increases the difficulty of treatment and the risk of recurrence.

  The 5-year survival rate for lung cancer is only 4-17.7%, and for patients undergoing chemotherapy, it's only 2%. For LUAD, the 5-year survival rate is less than 20%. 

  Molecular characterization of lung tumors has added new, increasingly effective and less toxic treatments to the lung cancer treatment options. This makes timely identification of genomic characteristics an urgent issue. 

  Research into novel molecular markers and therapeutic targets for lung cancer, particularly LUAD, is ongoing. For example, the role of the purine metabolic signaling pathway in tumorigenesis, tumor development, and immune escape is being investigated. CD73, a key rate-limiting enzyme in the extracellular purine metabolic pathway, is one such potential target. 

  Despite these advancements, there are still challenges in the process from lung cancer diagnosis to the interpretation of genomic data for treatment decisions, including occasional gaps, delays, and miscommunication. Efforts are being made to improve these processes.

  📚 Sources Used:

  • Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer
    Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC8079205

  • Serum Markers CA125, CA153, and CEA along with Inflammatory Cytokines in the Early Detection of Lung Cancer in High-Risk Populations
    Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9592194

  • Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project
    Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10159331

  • CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway
    Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9259339

sources_used:
  [{"title": "Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer", "source": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8079205", "timestamp": "2024-11-24T14:35:58.047801"}, {"title": "Serum Markers CA125, CA153, and CEA along with Inflammatory Cytokines in the Early Detection of Lung Cancer in High-Risk Populations", "source": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9592194", "timestamp": "2024-11-24T14:35:58.047816"}, {"title": "Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens \u2013 A multidisciplinary quality improvement project", "source": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10159331", "timestamp": "2024-11-24T14:35:58.047819"}, {"title": "CD73 (NT5E) Promotes the Proliferation and Metastasis of Lung Adenocarcinoma through the EGFR/AKT/mTOR Pathway", "source": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9259339", "timestamp": "2024-11-24T14:35:58.047822"}]


